<SEC-DOCUMENT>0001213900-23-062628.txt : 20230802
<SEC-HEADER>0001213900-23-062628.hdr.sgml : 20230802
<ACCEPTANCE-DATETIME>20230802170018
ACCESSION NUMBER:		0001213900-23-062628
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230802
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230802
DATE AS OF CHANGE:		20230802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		231136711

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea182689-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:ABVC="http://abvcpharma.com/20230802">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_ABVC_abvcpharma.com_20230802 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20230802_20230802 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20230802.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-08-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-02</xbrli:startDate>
        <xbrli:endDate>2023-08-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_905_edei--DocumentType_c20230802__20230802_zeOEnjU8ec98"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_900_edei--DocumentPeriodEndDate_c20230802__20230802_zopv4MKv23h6"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 2, 2023</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityRegistrantName_c20230802__20230802_z79cpjpB3xji"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityRegistrantName">ABVC BIOPHARMA, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20230802__20230802_zAvcVbuXMdgk"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20230802__20230802_zaFGQ8hi8jK9"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityFileNumber">001-40700</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityTaxIdentificationNumber_c20230802__20230802_zeIMDOXyZpdf"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(State or other jurisdiction<br />
of incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(IRS Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20230802__20230802_zRLyFmLyR5N4"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityAddressAddressLine1">44370 Old Warm Springs Blvd.</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20230802__20230802_z0Pxl0VbYnKf"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20230802__20230802_zGAWH70G5B44"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> </span></b></p></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressPostalZipCode_c20230802__20230802_z7NFxHc78ugf"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">(Address of principal executive offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number including area
code: <b>(<span id="xdx_90F_edei--CityAreaCode_c20230802__20230802_zPjFCEvhPTbd"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_903_edei--LocalPhoneNumber_c20230802__20230802_zPPw8M4zYcG7"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--WrittenCommunications_c20230802__20230802_zHIokcm4pY8l"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20230802__20230802_zWOBY3Qbgkyb"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20230802__20230802_zTp4tbBSQ0Nk"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20230802__20230802_zIIbUyw77qg4"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-size: 10pt">Title of Each Class</span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 20%; text-align: center"><span style="font-size: 10pt">Trading Symbol</span></td>
    <td style="vertical-align: top; width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 39%; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_908_edei--Security12bTitle_c20230802__20230802_zYpwRkFJIK4g"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20230802__20230802_zw5ul353BSXi"><ix:nonNumeric contextRef="AsOf2023-08-02" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20230802__20230802_za7yoTcKbGia"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule
12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20230802__20230802_zhFnEt34H0H8"><ix:nonNumeric contextRef="AsOf2023-08-02" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 1.01 Entry into Material Definitive Agreements</b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 31, 2023, the Company
entered into&#160;a <span style="font-size: 10pt">binding&#160;term&#160;sheet&#160;(the&#160;&#8220;Term&#160;Sheet&#8221;) with Xinnovation
Therapeutics Co., Ltd., a Company incorporated under the Law of People&#8217;s Republic of China (&#8220;Xinnovation&#8221;). The&#160;Term&#160;Sheet&#160;contemplates
that, pursuant to definitive agreements, Xinnovation will be granted an exclusive license to develop, manufacture, market, and distribute
ABV-1504 for Major Depressive Disorder (MDD) and ABV-1505 for Attention-Deficit/Hyperactivity Disorder, in the Chinese market and shall
bear the costs for clinical trials and product registration in China; the Company shall receive an initial license fee and royalty payments
ranging from 5% to 12% based on the projected annual net sales of the licensed drugs by Xinnovation in China (the &#8220;Licensing&#8221;).
</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If definitive agreements are
not completed and executed by July 31, 2024 or the parties otherwise mutually agree, the Term Sheet shall terminate. There can be no guarantee
that definitive agreements will be executed and the Licensing consummated on the terms contemplated by the&#160;Term&#160;Sheet, or at
all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The&#160;definitive agreements
and the Licensing are conditional on the satisfaction of a number of conditions, including satisfactory completion of due diligence, finalization
of the definitive agreements, regulatory approvals and the approval of those documents by the Company&#8217;s board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 1, 2023, the Company
issued a press release announcing the entry into the Term Sheet. A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary of the
terms of the Term Sheet is subject to, and qualified in its entirety by, the complete Term Sheet, which is attached as an exhibit to this
filing and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statement and Exhibits
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea182689ex10-1_abvcbio.htm"><span style="font-size: 10pt">Term Sheet dated July 31, 2023</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="ea182689ex99-1_abvcbio.htm">Press Release dated August 1, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">August 2, 2023</span></td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Uttam Patil</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>












</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk0qgvZNi4pYRYqIr9FuJdhmyyb+HclbGlvEZWFZZr4ZIXpiSQtTIcNxlmewx7qptEfIsURGe8bgSFfrBMLN8WKcZ219+/7AlAKDgRn11eQUhNZ6Nw6LBOR4INUgHoKSyVDBdCOir56SLU2B1htdgbYF7JgaNug1v7qEvX6SpfrVVh2QnSGbgOrLTn5DLFUMW7rrB/HVQZalIuq1E4kl06351tycpxrmFdahy3Xof6MPEL1JOw== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea182689ex10-1_abvcbio.htm
<DESCRIPTION>TERM SHEET DATED JULY 31, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Licensing Term Sheet</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">This legal binding Term Sheet ( &ldquo;Term Sheet&rdquo;) shall take
effect on the date of 31 July, 2023 (&rdquo; Effective Date&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#26412;&#20855;&#26377;&#27861;&#24459;&#32422;&#26463;&#21147;&#30340;Term
Sheet&#65288;&ldquo;Term Sheet&rdquo;&#65289;&#34987;&#35270;&#20026;&#20110;2023&#24180;7&#26376; 31 &#26085;&#65288;&ldquo;&#29983;&#25928;&#26085;&rdquo;&#65289;&#29983;&#25928;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Between &#32532;&#32422;&#26041;:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(1) ABVC BioPharma Inc., a company organized and existing under the
Laws of United States of America, with its registered office at 44370 Old Warm Springs Boulevard, Fremont, California 94538 USA (&ldquo;ABVC&rdquo;);
and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">ABVC BioPharma,
Inc.&#19968;&#23478;&#20381;&#25454;&#32654;&#22269;&#27861;&#24459;&#32452;&#24314;&#24182;&#23384;&#32493;&#30340;&#20844;&#21496;&#65292;&#20854;&#27880;&#20876;&#22320;&#22336;&#20026;44370
Old Warm Springs Boulevard, Fremont, California 94538 USA&#65288;&ldquo;<B>ABVC</B>&rdquo;&#65289;&#65307;&#21644;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(2) Xinnovation Therapeutics Co., Ltd., a company incorporated under
the Law of People&rsquo;s</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">Republic of China having its registered office at
3<SUP>rd</SUP> Floor, 66 Guigu 3<SUP>rd</SUP> Road, Luoxing Street, Jiashan, Zhejiang Province, China. (&ldquo;<B>Xinnovation</B>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">&#22025;&#20852;&#37995;&#31283;&#29983;&#29289;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;&#19968;&#23478;&#20381;&#25454;&#20013;&#21326;&#20154;&#27665;&#20849;&#21644;&#22269;&#27861;&#24459;&#32452;&#24314;&#24182;&#23384;&#32493;&#30340;&#20844;&#21496;&#65292;&#20854;&#27880;&#20876;&#22320;&#22336;&#20026;&#27993;&#27743;&#30465;&#22025;&#21892;&#21439;&#32599;&#26143;&#34903;&#36947;&#24402;&#35895;&#19977;&#36335;66&#21495;3&#27004;&#65288;&ldquo;&#37995;&#31283;&rdquo;&#65289;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">ABVC and Xinnovation shall be referred to individually as a &ldquo;Party&rdquo;
and collectively as the &ldquo;Parties&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC&#21644;&#37995;&#31283;&#21333;&#31216;&ldquo;&#19968;&#26041;&rdquo;&#65292;&#21512;&#31216;&ldquo;&#21452;&#26041;&rdquo;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of this Term Sheet is to outline the
main terms and conditions (the &ldquo;Key Terms&rdquo;) of the definitive agreement (as defined below) for licensing, clinical trial,
registration, manufacturing, supply and distribution of the Licensed Product (see Exhibit A) within the Territory (see Exhibit A). The
execution of the Definitive Agreement shall be contingent upon the following conditions:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#26412;Term Sheet&#30340;&#30446;&#30340;&#26159;&#27010;&#36848;&#21452;&#26041;&#27491;&#22312;&#32771;&#34385;&#32532;&#32467;&#30340;&#20851;&#20110;&#22312;&#21306;&#22495;&#65288;&#23450;&#20041;&#35265;&#38468;&#34920;A&#65289;&#20869;&#35768;&#21487;&#12289;&#20020;&#24202;&#12289;&#27880;&#20876;&#30003;&#25253;&#12289;&#29983;&#20135;&#12289;&#20379;&#24212;&#21644;&#20998;&#38144;&#26412;&#35768;&#21487;&#20135;&#21697;&#65288;&#23450;&#20041;&#35265;&#38468;&#34920;A&#65289;&#30340;&#26368;&#32456;&#21327;&#35758;&#65288;&#35265;&#20197;&#19979;&#23450;&#20041;&#65289;&#30340;&#20027;&#35201;&#26465;&#27454;&#21644;&#26465;&#20214;&#65288;&#20197;&#19979;&#31616;&#31216;&ldquo;&#20027;&#35201;&#26465;&#27454;&rdquo;&#65289;&#12290;&#26368;&#32456;&#21327;&#35758;&#30340;&#31614;&#32626;&#24212;&#22522;&#20110;&#20197;&#19979;&#26465;&#20214;&#65306;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(A) Upon on signing this term agreement, Xinnovation has the exclusive
right, until the expiration of this agreement, to negotiate and execute definitive licensing agreement for the licensed products with
ABVC.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">(B) Xinnovation has the right to team with partner(s), or transfer
the right to a third party to negotiate and execute definitive licensing agreement for the licensed products with ABVC. In such a case,
the definitive licensing agreement between the 3<SUP>rd</SUP> party and ABVC has to be agreed by Xinnovation, so that Xinnovation shall
sign a release form to transfer the licensing right to the 3<SUP>rd</SUP> party. Supplemental and appropriate agreements shall be signed
between Xinnovation and the 3<SUP>rd</SUP> party or between Xinnovation and ABVC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(C) The Parties shall negotiate and execute definitive
licensing agreement, supply agreement and manufacturing agreement (collectively, the &ldquo;Definitive Agreement&rdquo;) and reach mutual
agreement as to the other legal documents necessary to complete the transaction. The Definitive Agreement will be mutually satisfactory
to the Parties thereto in a form customary for transactions of this kind, with the Key Terms, and will, among other things, contain certain
representations, warranties, and covenants of ABVC with respect to the information delivered to Xinnovation related to the Licensed Products
and intellectual property that protects the Licensed Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">&#21452;&#26041;&#24212;&#21327;&#21830;&#24182;&#31614;&#35746;&#26368;&#32456;&#30340;&#35768;&#21487;&#21327;&#35758;&#12289;&#20379;&#24212;&#21327;&#35758;&#21450;&#29983;&#20135;&#21327;&#35758;&#65288;&#20197;&#19979;&#32479;&#31216;&ldquo;&#26368;&#32456;&#21327;&#35758;&rdquo;&#65289;&#65292;&#24182;&#23601;&#23545;&#23436;&#25104;&#20132;&#26131;&#25152;&#38656;&#30340;&#20854;&#20182;&#27861;&#24459;&#25991;&#20214;&#36798;&#25104;&#30456;&#20114;&#21327;&#23450;&#12290;&#26368;&#32456;&#21327;&#35758;&#24212;&#20197;&#21516;&#31867;&#20132;&#26131;&#30340;&#36890;&#29992;&#24418;&#24335;&#36798;&#21040;&#21452;&#26041;&#28385;&#24847;&#19988;&#21547;&#20027;&#35201;&#26465;&#27454;&#30340;&#21327;&#35758;&#65292;&#24182;&#21253;&#21547;ABVC&#23545;&#21521;&#37995;&#31283;&#25552;&#20379;&#20851;&#20110;&#35768;&#21487;&#20135;&#21697;&#20449;&#24687;&#20197;&#21450;&#23545;&#35768;&#21487;&#20135;&#21697;&#20445;&#25252;&#30340;&#30693;&#35782;&#20135;&#26435;&#20316;&#20986;&#22768;&#26126;&#12289;&#20445;&#35777;&#21450;&#25215;&#35834;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">(D) Xinnovation shall have completed satisfactorily
a due diligence investigation of the Licensed Product and any issues that may arise in the course of such investigation shall have been
resolved satisfactorily.</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 30pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#37995;&#31283;&#24212;&#23436;&#25104;&#23545;&#35768;&#21487;&#20135;&#21697;&#30340;&#23613;&#32844;&#35843;&#26597;&#24182;&#19988;&#36798;&#21040;&#28385;&#24847;&#30340;&#26631;&#20934;&#65292;&#35843;&#26597;&#36807;&#31243;&#20013;&#21487;&#33021;&#20986;&#29616;&#30340;&#20219;&#20309;&#38382;&#39064;&#24212;&#24471;&#21040;&#28385;&#24847;&#35299;&#20915;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">and &#21644;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">ABVC shall make available
or cause to be made available to Xinnovation, its advisors, and Representatives all information relating to the Licensed Product as Xinnovation
shall reasonably request and to discuss the Licensed Product with ABVC&rsquo;s Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ABVC&#24212;&#26681;&#25454;&#37995;&#31283;&#30340;&#21512;&#29702;&#35201;&#27714;&#65292;&#21521;&#37995;&#31283;&#12289;&#20854;&#39038;&#38382;&#21644;&#20195;&#34920;&#25552;&#20379;&#19982;&#35768;&#21487;&#20135;&#21697;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#30456;&#20851;&#30340;&#25152;&#26377;&#20449;&#24687;&#65292;&#24182;&#19982;ABVC&#30340;&#20195;&#34920;&#23545;&#35768;&#21487;&#20135;&#21697;&#20316;&#20986;&#35752;&#35770;&#12290;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">Starting from the Effective Date till the execution
of the Definite Agreement, ABVC and its stockholders, directors, officers, employees, affiliates, agents or advisors (including, without
limitation, attorneys, accountants, consultants, scientific collaborators, bankers, and financial advisors) (collectively, &ldquo;Representatives&rdquo;)
shall deal exclusively with Xinnovation with respect to any licensing in the same scope or similar arrangement surrounding the Licensed
Product. Further, neither ABVC nor any of its Representatives shall solicit, enter into, or continue any discussion, negotiations, or
agreement with, or provide information to any other person or entity other than Xinnovation relating to the Licensed Product. In addition,
during the period ABVC shall&nbsp;not enter into any agreement or understanding, whether oral or written, that would prevent or interfere
with the consummation of the Definitive Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0in">&#33258;&#29983;&#25928;&#26085;&#26399;&#36215;&#33267;&#26368;&#32456;&#21327;&#35758;&#31614;&#32626;&#65292;ABVC&#21450;&#20854;&#32929;&#19996;&#12289;&#33891;&#20107;&#12289;&#39640;&#31649;&#12289;&#38599;&#21592;&#12289;&#20851;&#32852;&#20844;&#21496;&#12289;&#20195;&#29702;&#25110;&#39038;&#38382;&#65288;&#21253;&#25324;&#20294;&#19981;&#38480;&#20110;&#24459;&#24072;&#12289;&#20250;&#35745;&#24072;&#12289;&#21672;&#35810;&#24072;&#12289;&#31185;&#23398;&#21512;&#20316;&#26041;&#12289;&#38134;&#34892;&#21644;&#36130;&#21153;&#39038;&#38382;&#65289;&#65288;&#32479;&#31216;&ldquo;&#20195;&#34920;&rdquo;&#65289;&#24212;&#19982;&#37995;&#31283;&#19987;&#38376;&#22788;&#29702;&#22260;&#32469;&#35768;&#21487;&#20135;&#21697;&#30340;&#35768;&#21487;&#25110;&#31867;&#20284;&#30340;&#23433;&#25490;&#12290;&#27492;&#22806;&#65292;ABVC&#25110;&#20854;&#20219;&#20309;&#20195;&#34920;&#22343;&#19981;&#24471;&#19982;&#37995;&#31283;&#20197;&#22806;&#30340;&#20219;&#20309;&#20854;&#20182;&#20154;&#22763;&#25110;&#23454;&#20307;&#23547;&#27714;&#12289;&#21551;&#21160;&#25110;&#32487;&#32493;&#35752;&#35770;&#12289;&#35848;&#21028;&#25110;&#25552;&#20379;&#19982;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#30340;&#20449;&#24687;&#12290;&#27492;&#22806;&#65292;&#22312;&#36825;&#26399;&#38388;&#20869;&#65292;ABVC&#19981;&#24471;&#31614;&#35746;&#20219;&#20309;&#20250;&#38459;&#27490;&#25110;&#24178;&#25200;&#26368;&#32456;&#21327;&#35758;&#23436;&#25104;&#30340;&#20219;&#20309;&#21327;&#35758;&#25110;&#35845;&#35299;&#65292;&#26080;&#35770;&#26159;&#21475;&#22836;&#30340;&#36824;&#26159;&#20070;&#38754;&#30340;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Parties agree to obtain
the other&rsquo;s written consent prior to any disclosures related to this Term Sheet or its information hereby, including the existence
and status thereof or the identity of the Parties thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#21452;&#26041;&#21516;&#24847;&#22312;&#25259;&#38706;&#19982;&#26412;Term
Sheet&#25110;&#20854;&#30456;&#20851;&#30340;&#20449;&#24687;&#65292;&#21253;&#25324;&#23427;&#30340;&#23384;&#22312;&#12289;&#29366;&#24577;&#25110;&#32773;&#26159;&#21452;&#26041;&#30340;&#36523;&#20221;&#21069;&#65292;&#38656;&#33719;&#24471;&#21478;&#19968;&#26041;&#30340;&#20070;&#38754;&#21516;&#24847;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Term Sheet can be amended, modify or revised
in writing upon mutual agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#32147;&#38617;&#26041;&#21516;&#24847;&#65292;&#24471;&#20197;&#26360;&#38754;&#22686;&#35036;&#20462;&#25913;&#20043;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Term Sheet shall terminate under the following
circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) on the execution of the Definitive Agreement
as defined by the signature of both Parties;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) both Parties fail to execute the Definitive
Agreement within 1 year of the Effective Date ; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) if mutually agreed by both Parties in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#26412;Term Sheet&#24212;&#22312;&#19979;&#21015;&#24773;&#20917;&#19979;&#32456;&#27490;&#65306;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(1) &#26368;&#32456;&#21327;&#35758;&#33719;&#24471;&#21452;&#26041;&#31614;&#32626;&#26102;&#32456;&#27490;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2) <FONT STYLE="font-family: Times New Roman, Times, Serif">&#21452;&#26041;&#26410;&#33021;&#22312;&#29983;&#25928;&#20043;&#26085;&#36215;&#19968;&#24180;&#20869;&#31614;&#32626;&#26368;&#32456;&#21327;&#35758;</FONT>&#65307;&#25110;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(3) &#32463;&#21452;&#26041;&#21327;&#21830;&#19968;&#33268;&#21518;&#20070;&#38754;&#21516;&#24847;&#21518;&#32456;&#27490;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Term Sheet shall be executed in English
and Chinese. Both languages have the same effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#26412;&#21327;&#35758;&#30001;&#20013;&#33521;&#25991;&#20889;&#25104;,
&#20004;&#31181;&#35821;&#35328;&#21516;&#31561;&#26377;&#25928;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Term Sheet shall be governed by and construed
in accordance with the law of Singapore. Any or all disputes arising from or in connection with the performance of the Term Sheet shall
be settled through negotiation by both Parties. If the negotiation fails, each Party submits to Singapore International Arbitration Committee
for the exclusive arbitration. The arbitration proceedings shall be conducted in English and Chinese.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#26412;Term
Sheet&#21463;&#26032;&#21152;&#22369;&#27861;&#24459;&#30340;&#31649;&#36758;&#24182;&#20381;&#20854;&#35299;&#37322;&#12290;&#21452;&#26041;&#22240;&#26412;
Term
Sheet&#24341;&#36215;&#21450;&#19982;&#20043;&#30456;&#20851;&#30340;&#20219;&#20309;&#20105;&#35758;&#65292;&#24212;&#39318;&#20808;&#21451;&#22909;&#21327;&#21830;&#35299;&#20915;&#12290;&#21327;&#21830;&#19981;&#25104;&#30340;&#24773;&#20917;&#19979;&#65292;&#20219;&#20309;&#19968;&#26041;&#22343;&#21487;&#21521;&#26032;&#21152;&#22369;&#22269;&#38469;&#20210;&#35009;&#22996;&#21592;&#20250;&#25552;&#20986;&#20210;&#35009;&#12290;&#20210;&#35009;&#31243;&#24207;&#20197;&#33521;&#25991;&#21644;&#20013;&#25991;&#36827;&#34892;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Parties agree that this Term Sheet may be executed
in one or more counterparts and by facsimile or scanned copy by email, each of which shall be considered an original and one and the
same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#21452;&#26041;&#21516;&#24847;&#65292;&#26412;Term
Sheet&#21487;&#31614;&#32626;&#19968;&#20221;&#25110;&#22810;&#20221;&#21103;&#26412;&#65292;&#24182;&#36890;&#36807;&#20256;&#30495;&#25110;&#20197;&#25195;&#25551;&#21103;&#26412;&#36890;&#36807;&#30005;&#23376;&#37038;&#20214;&#36865;&#36798;&#65292;&#27599;&#19968;&#20221;&#37117;&#24212;&#34987;&#35270;&#20026;&#21407;&#20214;&#21644;&#21516;&#19968;&#20221;&#25991;&#20070;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties have caused
this Agreement to be executed by themselves or their duly authorized officers, on the day and year first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#21452;&#26041;&#24050;&#32463;&#30001;&#20854;&#33258;&#36523;&#25110;&#20854;&#27491;&#24335;&#25480;&#26435;&#30340;&#31649;&#29702;&#20154;&#21592;&#20110;&#25991;&#39318;&#25152;&#36848;&#26085;&#26399;&#31614;&#32626;&#26412;&#21327;&#35758;&#65292;&#20197;&#36164;&#20026;&#35777;&#12290;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; width: 50%; border: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC BioPharma, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized Signature/Seal</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#25480;&#26435;&#20195;&#34920;&#31614;&#23383;</FONT>/<FONT STYLE="font-family: Times New Roman, Times, Serif">&#20844;&#31456;&#65306;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name<FONT STYLE="font-family: Times New Roman, Times, Serif">&#22995;&#21517;&#65306;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Uttam&nbsp;Yashwant Patil</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32844;&#21153;</FONT>:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CEO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date<FONT STYLE="font-family: Times New Roman, Times, Serif">&#26085;&#26399;&#65306;</FONT></P></TD>
    <TD STYLE="padding: 5.4pt; width: 50%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xinnovation Therapeutics Co., Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22025;&#20852;&#37995;&#31283;&#29983;&#29289;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Authorized Signature/Seal</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#25480;&#26435;&#20195;&#34920;&#31614;&#23383;</FONT>/<FONT STYLE="font-family: Times New Roman, Times, Serif">&#20844;&#31456;&#65306;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name<FONT STYLE="font-family: Times New Roman, Times, Serif">&#22995;&#21517;&#65306;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#31456;&#26032;</B>Jason Zheng</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title<FONT STYLE="font-family: Times New Roman, Times, Serif">&#32844;&#21153;&#65306;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CEO</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date<FONT STYLE="font-family: Times New Roman, Times, Serif">&#26085;&#26399;&#65306;</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit &#38468;&#20214;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; width: 29%; border: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LICENSEE</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#34987;&#35768;&#21487;&#26041;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 71%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Xinnovation Therapeutics Co., Ltd.</B>(&ldquo;Xinnovation&rdquo;)
    and its affiliates</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22025;&#20852;&#37995;&#31283;&#29983;&#29289;&#31185;&#25216;&#26377;&#38480;&#20844;&#21496;&#65288;&ldquo;&#37995;&#31283;&rdquo;&#65289;&#21450;&#20854;&#20851;&#32852;&#20844;&#21496;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LICENSOR</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#35768;&#21487;&#26041;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC BioPharma, Inc. (&ldquo;ABVC&rdquo;) and its affiliates</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC&#36745;&#26223;&#29983;&#25216;&#21307;&#33647;&#20844;&#21496;&#65288;&ldquo;ABVC&rdquo;&#65289;&#21450;&#20854;&#20851;&#32852;&#20844;&#21496;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>THIRD PARTY</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#31532;&#19977;&#26041;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&ldquo;Third Party&rdquo; means a person or entity other than
    Xinwen Biotech or ABVC or their respective affiliates.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;&#31532;&#19977;&#26041;&rdquo;&#31995;&#25351;&#37995;&#31283;&#25110;ABVC&#25110;&#20854;&#21508;&#33258;&#30340;&#20851;&#32852;&#20844;&#21496;&#20197;&#22806;&#30340;&#20010;&#20154;&#25110;&#23454;&#20307;&#12290;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EFFECTIVE DATE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#29983;&#25928;&#26085;&#26399;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The effective dates of Definitive Agreement related to the Licensed
    Product that would be the result of Parties&rsquo; discussions</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#21452;&#26041;&#35752;&#35770;&#21518;&#21516;&#24847;&#30340;&#19982;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#30340;&#26368;&#32456;&#21327;&#35758;&#29983;&#25928;&#26085;&#26399;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LICENSED PRODUCT</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#35768;&#21487;&#20135;&#21697;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">ABVC&rsquo;s single-herb botanical drug extract from the dry root
    of polygala tenuifolia willd (Yuan Zhi - Traditional Chinese Medicine) for treatment of ABV-1504 Major Depressive Disorder (MDD)
    and ABV-1505 Attention-Deficit/Hyperactivity Disorder (ADHD)</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC&#30340;&#20174;&#19977;&#21494;&#33609;&#24178;&#26681;&#65288;&#36828;&#24535;-&#20013;&#33609;&#33647;&#65289;&#25552;&#21462;&#30340;&#21333;&#33647;&#33609;&#26893;&#29289;&#33647;&#29289;&#65292;&#29992;&#20110;&#27835;&#30103;&#25233;&#37057;&#30151;&#36866;&#24212;&#30151;&#21450;&#27880;&#24847;&#21147;&#32570;&#38519;&#22810;&#21160;&#38556;&#30861;&#36866;&#24212;&#30151;&#30340;&#33647;&#29289;&#12290;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TERRITORY</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#21306;&#22495;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mainland China</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#20013;&#22269;&#22823;&#38470;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GOVERNING LAW</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#31649;&#36758;&#27861;&#24459;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Laws of Singapore.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#26032;&#21152;&#22369;&#27861;&#24459;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FIELD OF USE </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#36866;&#29992;&#39046;&#22495;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All human diseases</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#25152;&#26377;&#30340;&#20154;&#31867;&#30142;&#30149;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RIGHTS GRANTED</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#25480;&#20104;&#26435;&#21033;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">ABVC shall grant to Xinnovation an exclusive right within the
    Territory license to develop and commercialize the Licensed Product in the Territory within the Field of Use.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC&#24212;&#21521;&#37995;&#31283;&#25480;&#20104;&#21306;&#22495;&#20869;&#30340;&#29420;&#23478;&#35768;&#21487;&#65292;&#22312;&#21306;&#22495;&#36866;&#29992;&#39046;&#22495;&#20869;&#24320;&#21457;&#21644;&#21830;&#19994;&#21270;&#35768;&#21487;&#20135;&#21697;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">ABVC shall also grant to Xinnovation a right to sublicense to
    the third party, pre-agreed by ABVC, in the Territory.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC&#25480;&#20104;&#37995;&#31337;&#22312;Territory&#33539;&#22260;&#20869;&#65292;&#32463;&#30001;ABVC&#39044;&#20808;&#21516;&#24847;&#30340;&#31532;&#19977;&#26041;&#36827;&#34892;&#20877;&#25480;&#26435;&#30340;&#26435;&#21033;&#12290;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 5.4pt; border: black 1.5pt solid; vertical-align: top; width: 29%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RESPONSIBILITIES &amp; OBLIGATIONS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#36131;&#20219;&#20041;&#21153;</B></P></TD>
    <TD STYLE="border-top: black 1.5pt solid; text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 71%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC will be responsible for conducting the
    clinical development of the Licensed Product outside Territory and communicating the results as part of the Product Transfer (PT),
    which includes delivering the Licensed Product sufficient to support the clinical studies in Territory, delivering associated documents,
    manufacturing protocols, QC protocols, to enable Xinnovation to develop and commercialize the Licensed Product in Territory.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC&#23558;&#36127;&#36131;&#22312;&#21306;&#22495;&#22806;&#24320;&#23637;&#35768;&#21487;&#20135;&#21697;&#30340;&#20020;&#24202;&#24320;&#21457;&#65292;&#24182;&#20316;&#20026;&#20135;&#21697;&#36716;&#35753;(PT)&#30340;&#19968;&#37096;&#20998;&#20256;&#36798;&#32467;&#26524;&#65292;&#20854;&#20013;&#21253;&#25324;&#25552;&#20379;&#36275;&#20197;&#25903;&#25345;&#21306;&#22495;&#20869;&#20020;&#24202;&#30740;&#31350;&#30340;&#35768;&#21487;&#20135;&#21697;&#65292;&#20132;&#20184;&#30456;&#20851;&#25991;&#20214;&#12289;&#29983;&#20135;&#26041;&#26696;&#12289;&#36136;&#37327;&#26041;&#26696;&#65292;&#20351;&#37995;&#31283;&#33021;&#22815;&#22312;&#21306;&#22495;&#20869;&#24320;&#21457;&#21644;&#21830;&#19994;&#21270;&#35768;&#21487;&#20135;&#21697;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC will be responsible to secure the supply
    of the Licensed Product to Xinnovation in the Territory with an agreed price and quantity while Xinnovation will secure the purchase
    of the Licensed Products from ABVC in the Territory with committed volume. Further details are to be defined in the Definitive Agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC&#23558;&#36127;&#36131;&#20197;&#24050;&#21830;&#23450;&#30340;&#20215;&#26684;&#21644;&#25968;&#37327;&#21521;&#21306;&#22495;&#20869;&#30340;&#37995;&#31283;&#25552;&#20379;&#35768;&#21487;&#20135;&#21697;&#65292;&#24182;&#30830;&#20445;&#20379;&#24212;&#12290;&#21516;&#26102;&#65292;&#37995;&#31283;&#23558;&#20174;ABVC&#37319;&#36141;&#29992;&#20110;&#21306;&#22495;&#20869;&#30340;&#35768;&#21487;&#20135;&#21697;&#65292;&#24182;&#25215;&#35834;&#37319;&#36141;&#37327;&#12290;&#36827;&#19968;&#27493;&#30340;&#32454;&#33410;&#23558;&#22312;&#26368;&#32456;&#21327;&#35758;&#20013;&#23450;&#20041;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Xinnovation shall be responsible for completing
    regulatory filing of IND in the Territory.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#37995;&#31283;&#23558;&#36127;&#36131;&#23436;&#25104;&#21306;&#22495;&#20869;&#20020;&#24202;&#30740;&#31350;&#30003;&#35831;&#30340;&#22791;&#26696;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC will be responsible for providing the
    Licensed Product to Xinnovation at cost, to support clinical development in the Field of Use in the Territory.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC&#23558;&#36127;&#36131;&#20197;&#25104;&#26412;&#20215;&#21521;&#37995;&#31283;&#25552;&#20379;&#35768;&#21487;&#20135;&#21697;&#65292;&#20197;&#25903;&#25345;&#21306;&#22495;&#36866;&#29992;&#39046;&#22495;&#30340;&#20020;&#24202;&#24320;&#21457;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Xinnovation will be responsible for further
    development and commercialization of the Licensed Product in the Field of Use in the Territory, including any clinical development,
    regulatory affairs (including regulatory filings and approvals), and commercialization of the Licensed Product.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#37995;&#31283;&#23558;&#36127;&#36131;&#21306;&#22495;&#20869;&#22312;&#36866;&#29992;&#39046;&#22495;&#35768;&#21487;&#20135;&#21697;&#30340;&#36827;&#19968;&#27493;&#24320;&#21457;&#21644;&#21830;&#19994;&#21270;&#65292;&#21253;&#25324;&#20219;&#20309;&#20020;&#24202;&#24320;&#21457;&#12289;&#27880;&#20876;&#23457;&#25209;&#20107;&#21153;&#65288;&#21253;&#25324;&#27880;&#20876;&#30003;&#25253;&#22791;&#26696;&#21644;&#25209;&#20934;&#65289;&#20197;&#21450;&#35768;&#21487;&#20135;&#21697;&#30340;&#21830;&#19994;&#21270;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of this license, Xinnovation will
    grant ABVC a perpetual, royalty-free right to use and reference any development, regulatory, and market data associated with the
    Licensed Product in Xinnovation&rsquo;s control.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#20316;&#20026;&#26412;&#35768;&#21487;&#30340;&#19968;&#37096;&#20998;&#65292;&#37995;&#31283;&#23558;&#25480;&#20104;ABVC&#27704;&#20037;&#12289;&#26080;&#20607;&#30340;&#20351;&#29992;&#26435;&#65292;&#20351;&#29992;&#21644;&#21442;&#32771;&#37995;&#31283;&#25345;&#26377;&#30340;&#19982;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#30340;&#20219;&#20309;&#24320;&#21457;&#12289;&#27880;&#20876;&#30003;&#25253;&#21644;&#24066;&#22330;&#25968;&#25454;&#12290;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXCLUSIVITY/ </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-COMPETE</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#25490;&#20182;/&#19981;&#31454;&#20105;</B></P></TD>
    <TD STYLE="border-right: black 1.5pt solid; text-align: justify; padding: 5.4pt; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the collaboration, neither Parties or its affiliates will
    work on development of or commercialize in Territory any products containing Yuan Zhi as the sole active ingredient or in combination
    with one or more other active ingredients outside of this Agreement or without a specific mutually agreed to written plan for depression
    indication.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#22312;&#21512;&#20316;&#26399;&#38388;&#65292;&#20219;&#20309;&#19968;&#26041;&#25110;&#20854;&#20851;&#32852;&#20844;&#21496;&#19981;&#20250;&#22312;&#26412;&#21327;&#35758;&#20197;&#22806;&#25110;&#27809;&#26377;&#19968;&#20010;&#29305;&#23450;&#21452;&#26041;&#21516;&#24847;&#30340;&#20070;&#38754;&#35745;&#21010;&#22312;&#21306;&#22495;&#20869;&#20174;&#20107;&#20219;&#20309;&#21547;&#36828;&#24535;&#20026;&#21807;&#19968;&#27963;&#24615;&#25104;&#20998;&#25110;&#19982;&#19968;&#31181;&#25110;&#22810;&#31181;&#20854;&#20182;&#27963;&#24615;&#25104;&#20998;&#32467;&#21512;&#30340;&#27835;&#30103;&#25233;&#37057;&#30151;&#30340;&#20219;&#20309;&#20135;&#21697;&#30340;&#24320;&#21457;&#25110;&#21830;&#19994;&#21270;&#12290;</P></TD></TR>
  <TR>
    <TD STYLE="padding: 5.4pt; vertical-align: top; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TECHNOLOGY SHARING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#25216;&#26415;&#20998;&#20139;</B></P></TD>
    <TD STYLE="border-right: black 1.5pt solid; text-align: justify; padding: 5.4pt; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">After the Effective Date, and at a time to be agreed upon by Xinnovation
    and ABVC in the Definitive Agreement, ABVC would transfer to Xinnovation in English that data related to any Licensed Products in
    ABVC&rsquo;s possession and control that is required by regulatory authorities for opening an IND, NDA or equivalent (to be further
    specified in the Definitive Agreement).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#29983;&#25928;&#26085;&#26399;&#20043;&#21518;&#65292;&#20381;&#37995;&#31283;&#21644;ABVC&#22312;&#26368;&#32456;&#21327;&#35758;&#20013;&#21830;&#23450;&#30340;&#26102;&#38388;&#65292;ABVC&#23558;&#36716;&#20132;&#20854;&#25345;&#26377;&#21644;&#25511;&#21046;&#30340;&#20219;&#20309;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#29992;&#20110;IND&#12289;NDA&#25110;&#21516;&#31561;&#30003;&#35831;&#20013;&#30417;&#31649;&#26426;&#26500;&#35201;&#27714;&#25552;&#20379;&#30340;&#33521;&#35821;&#25968;&#25454;&#65288;&#22312;&#26368;&#32456;&#21327;&#35758;&#20013;&#36827;&#19968;&#27493;&#35268;&#23450;&#65289;&#12290;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding: 5.4pt; border: black 1.5pt solid; vertical-align: top; width: 29%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INTELLECTUAL PROPERTY RIGHTS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#30693;&#35782;&#20135;&#26435;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 71%"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intellectual Property means any patent, copyright, trade secret,
    trademark or other proprietary right&#65307;including all their applications , registrations, renewals and extensions.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#30693;&#35782;&#20135;&#26435;&#31995;&#25351;&#20219;&#20309;&#19987;&#21033;&#12289;&#29256;&#26435;&#12289;&#21830;&#19994;&#31192;&#23494;&#12289;&#21830;&#26631;&#25110;&#20854;&#20182;&#19987;&#26377;&#26435;&#65307;&#21253;&#25324;&#20854;&#25152;&#26377;&#30003;&#35831;&#12289;&#27880;&#20876;&#12289;&#32493;&#26399;&#21644;&#23637;&#26399;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Each Party or its Affiliates owns all rights, title and interest
    of the Intellectual Property developed or controlled by itself and will be responsible for filing and maintaining the Intellectual
    Property in the Territory at its own cost.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#27599;&#19968;&#26041;&#25110;&#20854;&#20851;&#32852;&#20844;&#21496;&#25317;&#26377;&#33258;&#24049;&#24320;&#21457;&#25110;&#25511;&#21046;&#30340;&#30693;&#35782;&#20135;&#26435;&#30340;&#20840;&#37096;&#26435;&#21033;&#12289;&#25152;&#26377;&#26435;&#21644;&#26435;&#30410;&#65292;&#24182;&#23558;&#36127;&#36131;&#30693;&#35782;&#20135;&#26435;&#22312;&#21306;&#22495;&#20869;&#30340;&#22791;&#26696;&#21450;&#32500;&#25252;&#65292;&#33258;&#34892;&#25215;&#25285;&#30456;&#20851;&#30340;&#36153;&#29992;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">During the License Term, ABVC, for itself and its Affiliates,
    hereby grants to Xinnovation, in accordance with the terms and conditions of the Definitive Agreement, an exclusive right and license
    under any and all Intellectual Property of the Licensed Product owned or controlled by ABVC or any of its Affiliates, to develop,
    register, seek and obtain Regulatory Approvals for, import, market, sell, after the approval of the Licensed Product into and within
    the Territory subject to the terms and conditions mentioned in the Definitive Agreement.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22312;&#35768;&#21487;&#26399;&#38480;&#20869;&#65292;ABVC&#20026;&#33258;&#24049;&#21450;&#20854;&#20851;&#32852;&#20844;&#21496;&#26681;&#25454;&#25480;&#26435;&#21327;&#35758;&#30340;&#26465;&#27454;&#21644;&#26465;&#20214;&#65292;&#21521;&#37995;&#31283;&#25480;&#20104;ABVC&#25110;&#20854;&#20219;&#20309;&#20851;&#32852;&#20844;&#21496;&#25317;&#26377;&#25110;&#25511;&#21046;&#30340;&#35768;&#21487;&#20135;&#21697;&#30340;&#30693;&#35782;&#20135;&#26435;&#29420;&#23478;&#26435;&#21033;&#21644;&#35768;&#21487;&#65292;&#29992;&#20110;&#37995;&#31283;&#26681;&#25454;&#26368;&#32456;&#21327;&#35758;&#25152;&#36848;&#30340;&#26465;&#27454;&#24320;&#21457;&#12289;&#27880;&#20876;&#12289;&#24182;&#23547;&#27714;&#21644;&#33719;&#24471;&#35768;&#21487;&#20135;&#21697;&#30340;&#27880;&#20876;&#25209;&#20934;&#21518;&#22312;&#21306;&#22495;&#20869;&#36827;&#21475;&#12289;&#25512;&#24191;&#21450;&#38144;&#21806;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Xinnovation will not sub-license the Intellectual Property of
    the Licensed Product to any Third Party without prior agreed by ABVC.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#26410;&#32463;ABVC&#20107;&#20808;&#21516;&#24847;&#65292;&#37995;&#31283;&#19981;&#24471;&#23558;&#35768;&#21487;&#20135;&#21697;&#30340;&#30693;&#35782;&#20135;&#26435;&#20877;&#35768;&#21487;&#32473;&#20219;&#20309;&#31532;&#19977;&#26041;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Any Intellectual Property related to the Licensed Product developed
    by Xinnovation during the License Term shall be owned by Xinnovation but shall be applied solely for the purpose of the Definitive
    Agreement. Xinnovation shall grant ABVC a perpetual, non-sublicensing, royalty-free right to use the Intellectual Property of the
    Licensed Product owned by Xinnovation outside the Territory.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22312;&#35768;&#21487;&#26399;&#38480;&#20869;&#65292;&#37995;&#31283;&#24320;&#21457;&#30340;&#19982;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#30340;&#20219;&#20309;&#30693;&#35782;&#20135;&#26435;&#20026;&#37995;&#31283;&#25152;&#26377;&#65292;&#20294;&#20165;&#29992;&#20110;&#26368;&#32456;&#21327;&#35758;&#30340;&#30446;&#30340;&#12290;&#37995;&#31283;&#24212;&#25480;&#20104;ABVC&#27704;&#20037;&#12289;&#19981;&#20877;&#35768;&#21487;&#12289;&#26080;&#20607;&#20351;&#29992;&#30340;&#26435;&#21033;&#65292;&#22312;&#21306;&#22495;&#20197;&#22806;&#20351;&#29992;&#37995;&#31283;&#25317;&#26377;&#30340;&#35768;&#21487;&#20135;&#21697;&#30340;&#30693;&#35782;&#20135;&#26435;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Upon termination of the Definitive Agreement, each Party shall
    cease to use the Intellectual Property of the Licensed Product of the other Party and return at the request of the other Party.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#26412;&#26368;&#32456;&#21327;&#35758;&#32456;&#27490;&#21518;&#65292;&#21508;&#26041;&#24212;&#20572;&#27490;&#20351;&#29992;&#21478;&#19968;&#26041;&#35768;&#21487;&#20135;&#21697;&#30340;&#30693;&#35782;&#20135;&#26435;&#65292;&#24182;&#24212;&#21478;&#19968;&#26041;&#30340;&#35201;&#27714;&#21518;&#36864;&#36824;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Each Party warrants it does not and will not infringe, violate
    or misappropriate any trademark, patent, copyright, industrial design, trade secret or any other intellectual property or proprietary
    right of any Third Party.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#21508;&#26041;&#20445;&#35777;&#27809;&#26377;&#12289;&#20063;&#19981;&#20250;&#20405;&#29359;&#20219;&#20309;&#31532;&#19977;&#26041;&#30340;&#21830;&#26631;&#12289;&#19987;&#21033;&#12289;&#29256;&#26435;&#12289;&#24037;&#19994;&#35774;&#35745;&#12289;&#21830;&#19994;&#31192;&#23494;&#25110;&#20219;&#20309;&#20854;&#20182;&#30693;&#35782;&#20135;&#26435;&#25110;&#19987;&#26377;&#26435;&#12290;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">No right, title or interest is granted to the other Party in the
    Definitive Agreement, whether expressly or by implication, to any technology or Intellectual Property rights owned by a Party other
    than pursuant to the terms of the Definitive Agreement.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#38500;&#26681;&#25454;&#26368;&#32456;&#21327;&#35758;&#30340;&#26465;&#27454;&#22806;&#65292;&#22312;&#26368;&#32456;&#21327;&#35758;&#20013;&#65292;&#19981;&#35770;&#26126;&#31034;&#25110;&#26263;&#31034;&#65292;&#19981;&#20250;&#25480;&#20104;&#21478;&#19968;&#26041;&#20854;&#25317;&#26377;&#30340;&#20219;&#20309;&#25216;&#26415;&#25110;&#30693;&#35782;&#20135;&#26435;&#30340;&#20219;&#20309;&#26435;&#21033;&#12289;&#25152;&#26377;&#26435;&#25110;&#26435;&#30410;&#65292;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Each Party will retain an unconditional and unlimited right of
    access, inclusion, citation, electronic or photo copy, and regulatory cross reference, without limitation, to any and all regulatory,
    technical, and scientific documentations, and any and all communications with any and all regulatory authorities in the other Party&rsquo;s
    Territory for all matters related to each Licensed Product during the License Term.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22312;&#35768;&#21487;&#26399;&#38480;&#20869;&#65292;&#21508;&#26041;&#23558;&#20445;&#26377;&#26080;&#26465;&#20214;&#21644;&#26080;&#38480;&#21046;&#30340;&#26435;&#21033;&#65292;&#35775;&#38382;&#12289;&#32435;&#20837;&#12289;&#24341;&#29992;&#12289;&#30005;&#23376;&#25110;&#22797;&#21360;&#21103;&#26412;&#20197;&#21450;&#27880;&#20876;&#20132;&#21449;&#24341;&#29992;&#20219;&#20309;&#35768;&#21487;&#20135;&#21697;&#30456;&#20851;&#30340;&#27880;&#20876;&#12289;&#25216;&#26415;&#21644;&#31185;&#23398;&#25991;&#20214;&#65292;&#20197;&#21450;&#21478;&#19968;&#26041;&#21306;&#22495;&#30340;&#30417;&#31649;&#26426;&#26500;&#25152;&#26377;&#20107;&#39033;&#30456;&#20851;&#30340;&#36890;&#20449;&#12290;</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border: black 1.5pt solid; width: 29%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MILESTONE &amp; ROYALTY PAYMENTS </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#37324;&#31243;&#30865;&#21450;&#38144;&#21806;&#25552;&#25104;&#25903;&#20184;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 71%"><P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Exhibit B.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#35265;&#38468;&#20214;B</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">In case of sublicense, and both parties agree that ABVC executes
    the definitive agreement directly with the sublicensee, in lieu of the definitive agreement with Xinnovation, Xinnovation shall be
    entitled to receive compensations, which are to be determined by the negotiation of definitive licensing agreement<BR>
    <BR>
    &#22914;&#26524;&#21457;&#29983;&#20877;&#25480;&#26435;&#30340;&#24773;&#20917;&#65292;&#19988;&#21452;&#26041;&#21516;&#24847;&#30001;ABVC&#30452;&#25509;&#19982;&#20877;&#25480;&#26435;&#20154;&#31614;&#35746;&#26368;&#32456;&#21327;&#35758;&#65292;&#20195;&#26367;&#19982;&#37995;&#31283;&#31614;&#35746;&#26368;&#32456;&#21327;&#35758;&#65292;&#21017;&#37995;&#31283;&#26377;&#26435;&#33719;&#24471;&#34917;&#20607;&#65292;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#34917;&#20607;&#26041;&#24335;&#23558;&#22312;</FONT>&#31614;&#35746;&#26368;&#32456;&#21327;&#35758;&#26102;&#19968;&#24182;&#35752;&#35770;&#12290;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TAX</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&#31246;&#36153;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Payments to Licensor as detailed in Exhibit B are likely considered
    Licensor&rsquo;s income generated in Territory. Licensor is responsible for income tax, value-added tax, and other related fees levied
    by Territory government authorities on these payments. If and to the extent that provision is made in law or regulation of Territory
    for withholding of taxes with respect to any such payment, Licensee shall pay such taxes on behalf of Licensor and provide Licensor
    with original receipt of such tax payments or withholding.</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#22312;&#38468;&#20214;B&#21015;&#20986;&#25903;&#20184;&#35768;&#21487;&#26041;&#30340;&#27454;&#39033;&#65292;&#21487;&#33021;&#34987;&#35270;&#20026;&#35768;&#21487;&#26041;&#22312;&#21306;&#22495;&#20869;&#20135;&#29983;&#30340;&#25910;&#20837;&#12290;&#35768;&#21487;&#26041;&#23558;&#23545;&#21306;&#22495;&#25919;&#24220;&#24403;&#23616;&#24449;&#25910;&#36825;&#20123;&#27454;&#39033;&#30340;&#25152;&#24471;&#31246;&#12289;&#22686;&#20540;&#31246;&#21644;&#20854;&#20182;&#30456;&#20851;&#36153;&#29992;&#36127;&#36131;&#12290;&#22914;&#26524;&#22312;&#21306;&#22495;&#27861;&#24459;&#25110;&#27861;&#35268;&#20013;&#35268;&#23450;&#20851;&#20110;&#20219;&#20309;&#27492;&#31867;&#25903;&#20184;&#38656;&#39044;&#25187;&#31246;&#27454;&#65292;&#34987;&#35768;&#21487;&#26041;&#23558;&#20195;&#34920;&#35768;&#21487;&#26041;&#25903;&#20184;&#27492;&#31867;&#31246;&#27454;&#65292;&#24182;&#21521;&#35768;&#21487;&#26041;&#25552;&#20379;&#35813;&#31867;&#31246;&#27454;&#25110;&#39044;&#25187;&#31246;&#27454;&#30340;&#23436;&#31246;&#20973;&#35777;&#27491;&#26412;&#12290;</P></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; text-align: justify; font-size: 10pt; width: 29%"><B>NET
    SALES &#20928;&#38144;&#21806;</B></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 71%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Net Sales&rdquo; means the total amount
    of invoices issued by the Licensee for selling the Product of each pack size in the Territory to the Third Parties responsible for
    distribution / logistics, minus the amount of allowable deduction items related to the Product actually provided to non-affiliates
    as follows:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;&#20928;&#38144;&#21806;&#39069;&rdquo;&#25351;&#34987;&#35768;&#21487;&#26041;&#22312;&#25480;&#26435;&#21306;&#22495;&#21521;&#36127;&#36131;&#20998;&#38144;/&#29289;&#27969;&#30340;&#31532;&#19977;&#26041;&#20844;&#21496;&#38144;&#21806;&#26412;&#20135;&#21697;&#20013;&#65292;&#23601;&#27599;&#20010;&#20135;&#21697;&#21253;&#35013;&#35268;&#26684;&#23545;&#24212;&#24320;&#20855;&#30340;&#21457;&#31080;&#24635;&#39069;&#65292;&#20943;&#21435;&#25552;&#20379;&#32473;&#38750;&#20851;&#32852;&#26041;&#23454;&#38469;&#21457;&#29983;&#30340;&#19979;&#21015;&#26412;&#20135;&#21697;&#30456;&#20851;&#30340;&#20801;&#35768;&#25187;&#38500;&#39033;&#30446;&#37329;&#39069;&#65306;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a) sales value added tax</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 12pt">&#38144;&#21806;&#22686;&#20540;&#31246;&#65307;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b) allowance, discount or rebate for rejection,
    defect, recall, return, retroactive price reduction</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 12pt">&#22240;&#25298;&#25910;&#12289;&#32570;&#38519;&#12289;&#21484;&#22238;&#12289;&#36864;&#36135;&#12289;&#36861;&#28335;&#38477;&#20215;&#25552;&#20379;&#30340;&#34917;&#20607;&#12289;&#25240;&#25187;&#25110;&#25240;&#35753;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net Sales shall be accounted in accordance
    with arm-length principles, industry standards and practices of the Territory, covering all sales of the Product to the Field of
    Use in the Territory. Any allowance, discount or rebate for any Third Party sales and marketing activities shall not be deducted
    from the Net Sales calculation.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#20928;&#38144;&#21806;&#39069;&#24212;&#25353;&#25480;&#26435;&#21306;&#22495;&#20869;&#30340;&#20844;&#24179;&#20132;&#26131;&#21407;&#21017;&#12289;&#34892;&#19994;&#26631;&#20934;&#21450;&#24815;&#20363;&#36827;&#34892;&#26680;&#31639;&#65292;&#35206;&#30422;&#26412;&#20135;&#21697;&#22312;&#25480;&#26435;&#21306;&#22495;&#30340;&#20840;&#37096;&#32456;&#31471;&#38144;&#21806;&#12290;&#20219;&#20309;&#31532;&#19977;&#26041;&#38144;&#21806;&#21644;&#33829;&#38144;&#27963;&#21160;&#30340;&#20219;&#20309;&#34917;&#36148;&#12289;&#25240;&#25187;&#25110;&#25240;&#35753;&#19981;&#24471;&#22312;&#20928;&#38144;&#21806;&#35745;&#31639;&#20013;&#25187;&#38500;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensee shall allow Licensor to appoint
    a Third Party independent auditor to audit the financial accounts of Licensee or its affiliates to confirm the reasonableness and
    accuracy of the Net Sales calculation of the Product each year during the License Term.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#34987;&#35768;&#21487;&#26041;&#24212;&#20801;&#35768;&#35768;&#21487;&#26041;&#22312;&#35768;&#21487;&#26399;&#38480;&#27599;&#20010;&#24180;&#24230;&#22996;&#27966;&#31532;&#19977;&#26041;&#29420;&#31435;&#23457;&#35745;&#24072;&#23545;&#34987;&#35768;&#21487;&#26041;&#25110;&#20854;&#38468;&#23646;&#20844;&#21496;&#23457;&#35745;&#26412;&#20135;&#21697;&#30340;&#36130;&#21153;&#36134;&#65292;&#20197;&#30830;&#35748;&#26412;&#20135;&#21697;&#20928;&#38144;&#21806;&#39069;&#35745;&#31639;&#30340;&#21512;&#29702;&#24615;&#21450;&#20934;&#30830;&#24615;&#12290;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LICENSE TERMS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#35768;&#21487;&#26399;&#38480;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The term of licensing for the Licensed Product
    in the Territory is 20 years.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#35768;&#21487;&#20135;&#21697;&#22312;&#21306;&#22495;&#20869;&#30340;&#35768;&#21487;&#26399;&#38480;&#20026;20&#24180;&#12290;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MANUFACTURING</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#29983;&#20135;</B></P></TD>
    <TD STYLE="text-align: justify; padding: 5.4pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Both Parties desire Licensee is responsible
    for the Licensed Product API manufacturing under CMO model as global primary supplier. Both Parties agree further study and analysis
    are to be performed for the feasibility from technical and financial perspective before the execution of related manufacturing agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#21452;&#26041;&#22343;&#24076;&#26395;&#34987;&#35768;&#21487;&#26041;&#20197;CMO&#27169;&#24335;&#36127;&#36131;&#35768;&#21487;&#20135;&#21697;&#30340;API&#21046;&#36896;&#65292;&#20316;&#20026;&#20840;&#29699;&#31532;&#19968;&#20379;&#24212;&#21830;&#12290;&#21452;&#26041;&#21516;&#24847;&#22312;&#31614;&#32626;&#30456;&#20851;&#21046;&#36896;&#21327;&#35758;&#20043;&#21069;&#65292;&#38656;&#35201;&#20174;&#25216;&#26415;&#21644;&#36130;&#21153;&#30340;&#35282;&#24230;&#23545;&#20854;&#21487;&#34892;&#24615;&#36827;&#34892;&#36827;&#19968;&#27493;&#30340;&#30740;&#31350;&#21644;&#20998;&#26512;&#12290;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing of Licensed Product finished
    product is subject to negotiation by both Parties. Further details are to be defined in the Definitive Agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#35768;&#21487;&#20135;&#21697;&#25104;&#21697;&#30340;&#21046;&#36896;&#30001;&#21452;&#26041;&#21327;&#21830;&#23436;&#25104;&#12290;&#36827;&#19968;&#27493;&#30340;&#32454;&#33410;&#23558;&#22312;&#26368;&#32456;&#21327;&#35758;&#20013;&#23450;&#20041;&#12290;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit &#38468;&#20214;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Ex
B-1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea182689ex99-1_abvcbio.htm
<DESCRIPTION>PRESS RELEASE DATED AUGUST 1, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT><B>ABVC
Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fremont, CA (August 1, 2023) &ndash; ABVC Biopharma, Inc. (NASDAQ:
ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, neurology, and ophthalmology,
today <FONT STYLE="background-color: white">announced </FONT>the signing of a legally binding term sheet with a prominent Chinese pharmaceutical
company, Xinnovation Therapeutics Co., Ltd that, subject to definitive agreements, is for the exclusive licensing of ABV-1504 for <FONT STYLE="background-color: #F7F7F8">Major
Depressive Disorder (MDD) </FONT>and ABV-1505 for Attention-Deficit/Hyperactivity Disorder in mainland China.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under this landmark agreement, Xinnovation Therapeutics Co., Ltd will
hold exclusive rights to develop, manufacture, market, and distribute our innovative drugs for <FONT STYLE="background-color: #F7F7F8">MDD</FONT>
and ADHD in the Chinese market and shall bear the costs for clinical trials and product registration in China. The licensing deal carries
a possible aggregate income of $20 million for ABVC. The term sheet outlines the key terms and conditions of the licensing agreement.
The final agreement, expected to be formally signed within one year, will specify the precise licensing terms, including the schedule
for milestone payments and other financial arrangements. As per the term sheet, ABVC expects to receive royalty payments ranging from
5% to 12% based on the projected annual net sales of licensed drugs in China, which we believe would bring ABVC&rsquo;s revenue ~$50 million
annually and ~$1 billion during the patent life of these products, if we achieve the expected amount of sales. The final agreement is
subject to the satisfaction of closing conditions, and the transaction will not occur if they are not satisfied or waived within one year.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are delighted to embark on this partnership with Xinnovation
Therapeutics Co., Ltd., which demonstrates our commitment to extending the reach of our groundbreaking therapeutics to patients in China,&rdquo;
said Dr. Uttam, CEO of ABVC. &ldquo;By leveraging Xinnovation Therapeutics Co., Ltd&rsquo;s strong presence and expertise in the Chinese market,
we aim to provide new hope and improved treatment options for individuals suffering from MDD and ADHD in China.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since our neurology products, ABV-1504 and ABV-1505, are new botanical
drugs of the extract from Polygala tenuifolia (Yuanzhi), a traditional Chinese medicine, Xinnovation will cooperate with other major pharmaceutical
companies in China to grow raw materials in compliance with GAP (Good Agricultural Practices) and to manufacture the drug substance in
compliance with GMP (Good Manufacturing Practices). By utilizing the vast agricultural resources and expertise available in China, we
can expedite the refinement and advancement of these new drugs, paving the way for faster and more efficient global dissemination.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white">We believe the Company&rsquo;s pipeline
products have great market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and
is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period.<SUP>1</SUP> According to the Polaris market
research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030
with a CAGR of 7.1% over the forecast period.<SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%20major%20depressive%20disorder%20(MDD,US%24%2011.51%20billion%20in%202022</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market-size-projected-to-reach-usd-32-14-billion-by-2032--with-cagr-of-7-1-study-by-polaris-market-research-301729196.html#:~:text=According%20to%20the%20research%20report,Deficit%20Hyperactivity%20Disorder%20(ADHD)%3F</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About ABVC BioPharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ABVC BioPharma is a clinical-stage biopharmaceutical
company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus<SUP>&reg;</SUP>) under development. For its drug
products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept
trials through Phase II of clinical development. The Company&rsquo;s network of research institutions includes Stanford University, University
of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus<SUP>&reg;</SUP>, theCompany intends to conduct global clinical
trials through Phase III.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains &ldquo;forward-looking statements.&rdquo;
Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo;
&ldquo;potential,&rdquo; or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions,
and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&rsquo;s control, and cannot be predicted
or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties
associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third
parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition;
(iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level
of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may
affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities and Exchange Commission
(SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents
free of charge on the SEC&rsquo;s website at&nbsp;<B>http://www.sec.gov</B>. The Company assumes no obligation to publicly update or revise
its forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tom Masterson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: tmasterson@allelecomms.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !# ' # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HI
MDLL<$32S2)'&@RSN< #U)-0V>HV6H*[65W!<!#AC%(&VGWQ0!9HJ@VN:2CLC
MZI9*RG!!N$!!_.D_M[1_^@M8_P#@0G^- &A14$E[:Q6HN9+F%+<X(E:0!#GI
MSTI\%Q#=0K-;S1RQ-T>-@P/XB@"2BBJUQJ%E:2I%<WEO#(_W$DE52W;@$\T
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M,_&>H^,]3C/]FZ:"UNC#CY02H_ ?,?<BH?%?CR7Q?X?TC0]*4F^U$JMY&O\
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>abvc-20230802.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aBZo7xRiXgen8uEb3JcWauNOcPtzpR3ielBtmp/bRkqjyYqVfIJ5yL/BE9mYaMM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:ABVC="http://abvcpharma.com/20230802" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20230802">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20230802_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20230802_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>abvc-20230802_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>abvc-20230802_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20230802.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140307589582448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  02,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370 Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea182689-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20230802.xsd" xlink:type="simple"/>
    <context id="AsOf2023-08-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2023-08-02</startDate>
            <endDate>2023-08-02</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-08-02">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-08-02">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-08-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-08-02">2023-08-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-08-02">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-08-02">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-08-02">001-40700</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-08-02">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-08-02">44370 Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-08-02">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-08-02">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-08-02">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-08-02">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-08-02">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-08-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-08-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-08-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-08-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-08-02">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-08-02">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-08-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-08-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
M]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NX
MZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#
MS"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;
M9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'
MGL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G
M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M"  )B )7EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M"  )B )7)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM
M?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(H
MND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++
M3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$
M%     @ "8@"5V60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&UL
MK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QX
MWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#
M4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$
MJ+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:
M!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U5
M9"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\
MUDX:?^:+X3]>?P%02P$"% ,4    "  )B )7!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  F( E>^
M;C9([0   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    (  F( E>97)PC$ 8  )PG   3              "  <L!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ "8@"5T+T_IA2!
MA1   !@              ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    (  F( E>?H!OPL0(  .(,   -              "  90,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ "8@"5Y>*NQS     $P(   L
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64$L%!@     )  D /@(  .@3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea182689-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea182689-8k_abvcbio.htm">ea182689-8k_abvcbio.htm</File>
    <File>abvc-20230802.xsd</File>
    <File>abvc-20230802_lab.xml</File>
    <File>abvc-20230802_pre.xml</File>
    <File>ea182689ex10-1_abvcbio.htm</File>
    <File>ea182689ex99-1_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea182689-8k_abvcbio.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea182689-8k_abvcbio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20230802_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20230802_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20230802.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20230802",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea182689-8k_abvcbio.htm",
      "contextRef": "AsOf2023-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://abvcpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea182689-8k_abvcbio.htm",
      "contextRef": "AsOf2023-08-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-23-062628-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-062628-xbrl.zip
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M\&$?V$-"/60Z)KSHT=!NTV'<%7(H<I2<L]8F*O9_*5%@Z#MB*'*4-+3&8L/
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M9RQA6TZ_4L_G6O*VZO .=OZA=SU#=SEC[WJ&[H+^>7<]XV6//.\#_+V+A0A
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M%,R!F#@. /ZUR&$E:8JHP5W KZAQH<HZC0O\1,UQ6<0E4DC1 ;09%= ACFS
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MD[W]XT/K[>'Q\=G'O;=')[_\UT_V3^+OCWL'!_+O6X_D*IE5E_BH_9^*Q8B
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M4$L! A0#%     @ "8@"5_OR5"D5%   /VL  !<              ( !%A8
M &5A,3@R-C@Y+3AK7V%B=F-B:6\N:'1M4$L! A0#%     @ "8@"5P%QUK-Q
M,P  W#(! !H              ( !8"H  &5A,3@R-C@Y97@Q,"TQ7V%B=F-B
M:6\N:'1M4$L! A0#%     @ "8@"5S>\%;Y]#@  +B\  !H
M ( !"5X  &5A,3@R-C@Y97@Y.2TQ7V%B=F-B:6\N:'1M4$L%!@     &  8
*F@$  +YL      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
